Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.

CATX | US

Overview

Corporate Details

ISIN(s):
US46489V1044 (+1 more)
LEI:
Country:
United States of America
Address:
2401 ELLIOTT AVENUE, 98121 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company pioneering advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its proprietary technology platform uses a revolutionary lead-212 (Pb-212) based approach, conjugating radioisotopes to high-affinity targeting peptides. This theranostic method allows physicians to first image tumors to confirm targets and then deliver potent, short-range alpha radiation directly to cancer cells, aiming to maximize efficacy while minimizing damage to surrounding healthy tissue. The company's clinical pipeline is focused on oncology, with programs targeting melanoma, neuroendocrine tumors, and other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Perspective Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perspective Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perspective Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America INMB
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America TIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.